Beyond-Use Date (BUD)

A Beyond-Use Date (BUD) is the date or time after which a compounded preparation may not be used, calculated under USP 797 (sterile compounding) or USP 795 (non-sterile compounding) standards. USP 797 BUD ceilings are categorized by the controls applied during compounding: Category 1 carries a 12-hour BUD; Category 2 ranges by storage conditions from 4 days room temperature to 90 days frozen; Category 3 (with the most rigorous controls including sterility testing) can support BUDs up to 180 days.

How Beyond-Use Date assignment works

USP 797 BUD assignment follows a categorization framework. Category 1 applies to compounding performed in a segregated compounding area with the lowest controls and carries the shortest BUD. Category 2 applies to compounding in an ISO Class 7 buffer room and supports a range of BUDs based on storage conditions and whether the source is sterile or non-sterile. Category 3 applies to compounding under the most rigorous controls (PEC and SEC requirements, microbial monitoring at extended frequency, sterility testing, container closure integrity testing) and supports the longest BUDs.

USP 795 (non-sterile compounding) uses a parallel framework with different BUD ceilings. Documentation for each compounded preparation must record the category determination, the storage conditions, and the BUD assigned. FDA inspection and state board audit findings commonly cite BUD documentation gaps as a foundation for further enforcement.

When BUD requirements apply

BUD requirements apply to every compounded preparation in every compounding facility: 503A pharmacies, 503B outsourcing facilities, hospital pharmacies that compound sterile preparations, and ambulatory infusion centers. The BUD assignment is enforceable through USP-incorporating state pharmacy practice acts, through FDA cGMP inspection at 503B facilities, and through state board licensing inspection at 503A pharmacies.

The compounder's exposure under BUD findings

BUD documentation gaps can support Form 483 observations, FDA Warning Letters, state board discipline, and (where the BUD-related conduct produced patient harm) civil litigation. Dispensing of preparations beyond the assigned BUD can also support enforcement under the Federal Food, Drug, and Cosmetic Act misbranding and adulteration framework. The defense framework focuses on the contemporaneous BUD determination record, the category-assignment supporting documentation (environmental monitoring, sterility testing, PEC certification), and the corrective action where documentation gaps are identified.

Related terms

• USP 797 and 800 The USP General Chapters that set the BUD framework for sterile compounding and hazardous drug handling.
• 503A and 503B The two compounding pathways under which BUD assignment is most often audited.
• cGMP The FDA cGMP framework that imposes parallel BUD-equivalent requirements on 503B facilities.
• Form 483 The FDA inspectional observations document that frequently cites BUD documentation gaps.

See also

• Practice area
  USP 797/800 Compounding Defense

  The full USP compliance defense framework including BUD documentation.

• Practice area
  Compounding Pharmacy Defense

  The compounding defense pillar spanning 503A and 503B regulatory pathways and the full USP compliance framework.